Tuesday, 20 Aug 2019

You are here

The RheumNow Week in Review – Methotrexate CIRT Study (5.25.18)

Dr. Jack Cush reviews this past week's news from RheumNow.com - the risk of Cutaneous and Systemic LE, increasing flu vaccination, higher risk of VTE, MPO predictions, new drug for GIOP and CIRT - MTX in cardiovascular risk patients.

  1. Population study in Denmark shows the incidence of cutaneous LE to be 2.74/100,000 with a female:male ratio of 4:1 - the 10 year risk of these subsequently developing a dx of SLE was 12.9% (highest in women & SCLE pts) http://bit.ly/2IGoPQB
  2. Registry of 509 women with SLE had 719 children showed that compared to matched controls, children born to mothers with SLE had No greater risk of a systemic rheumatic autoimmune diagnoses. http://bit.ly/2GO37V0
  3. NEJM study of 1945 Kawasakis pts with >60% of pts < 4 months of age having onset in summer and fall in more. but > 60% of thos over 83 months had onset in winter and spring https://t.co/HAG9ZvQy8A
  4. Sandoz announces the approval of its infliximab biosimilarZessly (infliximab) by the European Commission. It is approved for use in RA, , adult & pediatric Crohn’s, adult & pediatric ulcerative colitis, AS, PsA and plaque psoriasis https://t.co/V0PJHbeLSp
  5. Not all that clear what is the best PFT for pts w/ Scleroderma Lung Disease, Some prefer the FVC, while others advocate for the DLCO or TLC. Do all 3! https://t.co/xNkpgGiYsv
  6. >50% of RA pts fail to receive influenza vaccination (highest in Younger, infrequent visits, Hi ESR, negative vaccine views). The problem was cut in half by using a multimodal intervention (education, EMR alerts, weekly provider-e-mail reminders) https://t.co/H8BxrLVAri
  7. Study of 85 RA patients demonstrates a prothrombotic tendency that is predicted by those with higher DAS-28, CRP, and platelet counts. https://t.co/wqU8XNzIDK
  8. Based on the recommendation of the Data Monitoring Committee, Regeneron has halted its phase III trial of fasinumab (anti- Nerve Growth Factor mAb), in OA pts w/ knee, hip or low back pain. https://t.co/ZwyjJbNzjm
  9. Paul Ridker, MD announced the NIH stopped enrolling the CIRT trial; MTX vs PBO in high risk (non-RA) pts looking at CV outcomes. DSMB rec. stopping after 4,786/7000 enrolled, not for safety, but because of enough efficacy data. Look for results in 11/18 https://t.co/n4PGybItkS
  10. RA pts have a 2 fold risk of osteoporosis-related fractures. High titer CCP levels assoc. w/ lower BMD and lean body mass assoc w/ higher BMD https://t.co/3cxPaiNIn6
  11. FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis 
  12. MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.

RheumNow Podcast – FDA Hyperactivity (7.26.19)

Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com